Corey J. Langer, MD
Medical Oncology

Corey J. Langer, MD

Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 2nd Floor West
View 1 additional location
Penn Medicine Provider

About me

  • Director, Thoracic Oncology
  • Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

My education and training

  • Boston University School of MedicineMedical School
  • Graduate HospitalResidency
  • Penn Presbyterian Medical CenterFellowship
  • Fox Chase Cancer CenterFellowship
Watch video featuring Corey J. Langer, MD on YouTube

Spoken languages

English
English

Reviews

Average Rating

772 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
September 2026
Dr.Langer is one of the best in the world!
Anonymous
September 2026
He is the best of the best. My favorite doctor of all time.
Anonymous
September 2026
Thorough, knowledgeable, personable, easy to talk to.
Anonymous
September 2026
He is very knowledgeable and explains issues very clearly.

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Langer is a Penn Medicine physician.

Qualifications and experience

Treatments and conditions

Research

Publications

Gerber DE, Wang Y, Langer CJ, Khullar OV, Kozono DE, Cornelius LA, Forde PM, Nwaneri MO, Neal JW, Talsania A, Leal TA, Patel M, Donthireddy KR, Waqar SN, Chaft JE, Govindan R, Sands JM, Malik S, Li T, Sun Z, Stinchcombe TE, Vokes EE, Mandrekar SJ, Oxnard GR, Carbone DP, Ramalingam SS. Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial , Lancet Respir Med: 2026


Barsouk AA, Yaskolko M, Sussman JH, Sun L, Singh AP, Cohen RB, Aggarwal C, Marmarelis ME, Langer CJ. Poor Performance Status Associated With Inferior Tarlatamab Outcomes in a Large, Multi-institution Real-World Database of Patients With 2L + ES-SCLC , Clin Lung Cancer, 27: 2026,50-55


Bleiberg BA, Scholes DG, Reed-Guy L, Dravid D, Sun LL, Singh AP, Cohen RB, Langer CJ, Marmarelis ME, Aggarwal C. Erratum to "The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing" [J. Liq. Biopsy 12 (2026) 100461] , J Liq Biopsy, 12: 2026,100472


Bleiberg BA, Reed-Guy L, Cohen RB, Aggarwal C, Langer CJ, Singh AP, Marmarelis ME. Carboplatin plus pemetrexed versus pemetrexed alone in advanced thymoma and thymic carcinoma: a retrospective cohort study , Front Oncol, 16: 2026,1795920


Bleiberg BA, Scholes DG, Reed-Guy L, Dravid D, Sun LL, Singh AP, Cohen RB, Langer CJ, Marmarelis ME, Aggarwal C. The incremental value of liquid biopsy in the initial evaluation of patients with metastatic non-small cell lung cancer undergoing tissue-based molecular testing , J Liq Biopsy, 12: 2026,100461


Barsouk A, Heidlauf A, Goel K, Rushkin L, Anran Huang A, Elghawy O, Yu C, Wang L, Yang D, Kurian M, Reed-Guy L, Sun L, Singh A, Aggarwal C, Cohen RB, Langer C, Marmarelis ME. Osimertinib dose-reduction and survival in 1L EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) , Lung Cancer: 2026


Wang W, Scholes DG, Watts AC, Roy MA, Singhal S, Kucharczuk JC, Jarrar D, Predina J, Pechet TTV, Sun LL, Singh AP, Cohen RB, Langer CJ, Aggarwal C, Marmarelis ME. EMBER-Lung: Electronic Medical Record Boosting Molecular Testing in Early-Stage Non-Small Cell Lung Cancer , JCO Precis Oncol: 2026


Friedes C, Iocolano M, Yegya-Raman N, Kucharczuk JC, Pechet TTV, Cohen RB, Aggarwal C, Marmarelis ME, Levin WP, Cengel KA, Ciunci CA, D'Avella C, Singh AP, Davis CW, Langer CJ, Bradley J, Feigenberg SJ. Real World Radiographic Response Rates and Preoperative Attrition in Patients With Non-Small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoimmunotherapy , Am J Clin Oncol: 2025


Langer CJ, Harris J, Horwitz EM, Kies M, Ad VB, Wong SJ, Caudell JJ, Zeitzer KL, Spencer SA, Zhang Q, Yom SS, Le QT. Phase 2 Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Long-term Follow-up of NRG Oncology Radiation Therapy Oncology Group Protocol 9911 , Int J Radiat Oncol Biol Phys, 124: 2025,50-60


Bazhenova L, Hodgson JG, Camidge DR, Langer CJ, Huber RM, Kim DW, Reckamp KL, Ahn MJ, Tan DSW, Patel JD, Vincent S, Li C, Humphries MJ, Zhang P, Rivera VM, Gettinger S. Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status , Clin Lung Cancer: 2025